ARS Pharmaceuticals (SPRY) Net Income towards Common Stockholders (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$95.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 156.94% year-over-year to -$95.9 million; the trailing twelve-month figure through Mar 2026 stood at -$474.8 million (down 123.05% YoY), and the FY2025 full-year result was -$171.3 million, down 2241.76% from the prior year.
• Net Income towards Common Stockholders declined to -$95.9 million in Q1 2026, from -$43.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $47.3 million in Q4 2024 to a low of -$39.4 billion in Q1 2023.
• A 5-year average of -$5.5 billion and a median of -$67.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders slumped 339646.93% in 2023 and surged 571.87% in 2024, its largest moves.
• Tracing SPRY's Net Income towards Common Stockholders over 5 years: stood at -$15.1 million in 2022, then jumped by 33.83% to -$10.0 million in 2023, then surged by 571.87% to $47.3 million in 2024, then sank by 192.39% to -$43.7 million in 2025, then tumbled by 119.7% to -$95.9 million in 2026.
• Business Quant data shows SPRY's Net Income towards Common Stockholders at -$95.9 million in Q1 2026, -$43.7 million in Q4 2025, and -$113.0 million in Q3 2025.